Targeting DNA repair mechanisms in cancers with BRCA1 mutations
Assessing DNA polymerase theta as a therapeutic target in BRCA1 mutant cancer
['FUNDING_R01'] · RESEARCH INST OF FOX CHASE CAN CTR · NIH-11026342
This study is looking at how a special protein called DNA polymerase theta can be used to create new treatments for cancers with BRCA1 gene mutations, aiming to find ways to target and kill the cancer cells while keeping healthy cells safe.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | RESEARCH INST OF FOX CHASE CAN CTR (nih funded) |
| Locations | 1 site (PHILADELPHIA, UNITED STATES) |
| Trial ID | NIH-11026342 on ClinicalTrials.gov |
What this research studies
This research investigates how DNA polymerase theta (Polθ) can be targeted to treat cancers that have mutations in the BRCA1 gene. By understanding the mechanisms that activate a specific DNA repair process in these cancer cells, the researchers aim to develop small molecule inhibitors that can selectively kill BRCA1 mutant cells while sparing healthy cells. The study will explore the relationship between Polθ activity and the effectiveness of existing cancer treatments, potentially leading to more effective therapies for patients with BRCA1 mutations.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with cancers that have BRCA1 mutations.
Not a fit: Patients with BRCA1 wild-type cancers or those without BRCA1 mutations may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new targeted therapies that improve treatment outcomes for patients with BRCA1 mutant cancers.
How similar studies have performed: Other research has shown promising results in targeting DNA repair mechanisms in cancer, suggesting that this approach could be effective.
Where this research is happening
PHILADELPHIA, UNITED STATES
- RESEARCH INST OF FOX CHASE CAN CTR — PHILADELPHIA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: JOHNSON, NEIL — RESEARCH INST OF FOX CHASE CAN CTR
- Study coordinator: JOHNSON, NEIL
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: anti-cancer therapy